The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2024 | The impact of clonal hematopoiesis on outcomes of ALL
Caner Saygin, MD, University of Chicago, Chicago, IL, discusses a study investigating the role of myeloid mutations in therapy-related acute lymphoblastic leukemia (ALL). This study found that patients with TP53 mutations and clonal hematopoiesis of indeterminate potential (CHIP) had inferior outcomes compared to those without. Single-cell proteogenomic analysis indicated that these myeloid mutations were present years before ALL onset, underscoring the importance of tracking clonal hematopoiesis in high-risk patients and considering treatments to prevent progression. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
